ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2021
Management of lung transplantation in the COVID-19 era-An international survey.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- COVID-19 and solid organ transplantation: Finding the right balance.Transplantation reviews (Orlando, Fla.) · 2022Pooled it
- CT-derived skeletal muscle predicts lung transplant approval.JHLT open · 2026Article
- An Interpretive Description of Patient and Provider Perspectives on the Impact of the COVID-19 Pandemic on Lung Transplant Care Access and Service Delivery in Alberta, Canada.Journal of transplantation · 2025Article
- Management of immunosuppression in lung transplant recipients and COVID-19 outcomes: an observational retrospective cohort-study.BMC infectious diseases · 2024Observational
- Time Trends in Clinical Characteristics and Hospital Outcomes of Hospitalizations for Lung Transplantation in COPD Patients in Spain from 2016 to 2020-Impact of the COVID-19 Pandemic.Journal of clinical medicine · 2023Article
- New Aspects of Lung Transplantation: A Narrative Overview Covering Important Aspects of Perioperative Management.Life (Basel, Switzerland) · 2022Review
- Living-Donor Lung Transplantation for Post-COVID-19 Respiratory Failure.The Annals of thoracic surgery · 2022Article
- Development of an organ procurement team in South Australia in response to COVID-19.ANZ journal of surgery · 2022Review
- How COVID-19 Affects Lung Transplantation: A Comprehensive Review.Journal of clinical medicine · 2022Review
- Lung Transplant as a Treatment for Patients with End-Stage Respiratory Failure Due to COVID-19.Transplantation proceedings · 2022Article
- Effects of the COVID-19 Pandemic on Solid Organ Transplantation During 2020 in Poland Compared with Countries in Western Europe, Asia, and North America: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2021Review
- Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review.Innovation (Cambridge (Mass.)) · 2021Review
- A Single-Center Experience with Lung Transplants During the COVID-19 Pandemic.Annals of transplantation · 2021Article
- Framework for Solid-Organ Transplantation During COVID-19 Pandemic in Europe.Risk management and healthcare policy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is unknown if solid organ transplant recipients are at higher risk for severe COVID-19. The management of a lung transplantation (LTx) program and the therapeutic strategies to adapt the immunosuppressive regimen and antiviral measures is a major issue in the COVID-19 era, but little is known about worldwide practice. We sent out to 180 LTx centers worldwide in June 2020 a survey with 63 questions, both regarding the management of a LTx program in the COVID-19 era and the therapeutic strategies to treat COVID-19 LTx recipients. We received a total of 78 responses from 15 countries. Among participants, 81% declared a reduction of the activity and 47% restricted LTx for urgent cases only. Sixteen centers observed deaths on waiting listed patients and eight centers performed LTx for COVID-19 disease. In 62% of the centers, COVID-19 was diagnosed in LTx recipients, most of them not severe cases. The most common immunosuppressive management included a decreased dose or pausing of the cell cycle inhibitors. Remdesivir, hydroxychloroquine, and azithromycin were the most proposed antiviral strategies. Most of the centers have been affected by the COVID-19 pandemic and proposed an active therapeutic strategy to treat LTx recipients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.